A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.
Repository Usage Stats
Targeting multiple regulators of tumor angiogenesis have the potential to improve treatment efficacy. Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor and ABT-510 is a synthetic analog of thrombospondin, an endogenous angiogenesis inhibitor. Dual inhibition may result in additional benefit. We evaluated the safety, tolerability, and efficacy of the combination of bevacizumab plus ABT-510 in patients with refractory solid tumors. We also explored the effects of these agents on plasma-based biomarkers and wound angiogenesis. Thirty-four evaluable subjects were enrolled and received study drug. Therapy was well tolerated; minimal treatment-related grade 3/4 toxicity was observed. One patient treated at dose level 1 had a partial response and five other patients treated at the recommended phase II dose had prolonged stable disease for more than 1 year. Biomarker evaluation revealed increased levels of D-dimer, von Willebrand factor, placental growth factor, and stromal-derived factor 1 in response to treatment with the combination of bevacizumab and ABT-510. Data suggest that continued evaluation of combination antiangiogenesis therapies may be clinically useful.
advanced solid tumors
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Dose-Response Relationship, Drug
Published Version (Please cite this version)10.1002/cam4.65
Publication InfoBendell, JC; Blobe, GC; Cushman, SM; Dellinger, Andrew; Gockerman, J; Hurwitz, HI; ... Uronis, HE (2013). A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. Cancer Med, 2(3). pp. 316-324. 10.1002/cam4.65. Retrieved from https://hdl.handle.net/10161/11086.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Professor Emeritus of Medicine
My research effort is involved in clinical research studies through the CALGB as well as several sub interests. My interest is the use of 131I MIBG in the treatment of carcinoids. We have completed a dose seeking study to determine the maximum tolerated dose. This has been completed and this paper is in preparation for publication. We plan to do an additional study of randomization in patients with this agent to see if we can determine an objective response rate in a controlled group
Professor of Medicine
We are studying the use of immune therapies to treat various cancers, including gastrointestinal, breast, and lung cancers and melanoma. These therapies include vaccines based on dendritic cells developed in our laboratory as well as vaccines based on peptides, viral vectors, and DNA plasmids. Our group is also a national leader in the development and use of laboratory assays for demonstrating immunologic responses to cancer vaccines. Finally, we are developing immunotherapies based on ado
Alphabetical list of authors with Scholars@Duke profiles.